J&J Unit Settles With Lannett in Patent Suit Over Uptravi Copies

Actelion Pharmaceuticals US Inc. settled a federal lawsuit that accused Lannet Co.'s proposed copies of Uptravi tablets of infringing two patents the Johnson & Johnson unit licenses from Nippon Shinyaku Co. for the blockbuster pulmonary arterial hypertension drug.

The agreement blocks Lannett’s generic versions of Uptravi’s tablet formulations until US Patent Nos. 8,791,122 and 9,284,280 expire “unless otherwise authorized” by Actelion and Nippon Shinyaku, according to a consent judgment and order of permanent injunction approved Thursday in the US District Court for the District of Delaware.

• The patents cover a crystal form of selexipag, Uptravi’s active ingredient, and its use ...